Back to Search
MARY ELLEN MOYNAHAN, MD
MD
Medical Oncology Physician
NPI: 1568433522Individual
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
178161(NY)
Research & Publications (20)
The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans.
PMID 12483515·Oncogene·2002
6-review
BRCA2 is required for homology-directed repair of chromosomal breaks.
PMID 11239455·Mol Cell·2001
7-preclinical
Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation.
PMID 11406561·Cancer Res·2001
7-preclinical
A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma.
PMID 18751888·Breast Cancer Res Treat·2009
3-trial
PIK3CA mutation associates with improved outcome in breast cancer.
PMID 19671852·Clin Cancer Res·2009
8-other
Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible.
PMID 18952555·Clin Breast Cancer·2008
3-trial
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
PMID 18323546·J Clin Oncol·2008
3-trial
FDA viewpoint: St. Jude Medical's Riata ST leads.
PMID 18181904·Pacing Clin Electrophysiol·2008
8-other
Pacemaker and ICD generator malfunctions: analysis of Food and Drug Administration annual reports.
PMID 16639048·JAMA·2006
8-other
A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.
PMID 15803362·Breast Cancer Res Treat·2005
3-trial
Cardiac resynchronization devices: the Food and Drug Administration's regulatory considerations.
PMID 16360066·J Am Coll Cardiol·2005
8-other
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer.
PMID 15355903·Clin Cancer Res·2004
3-trial
Involvement of mammalian Mus81 in genome integrity and tumor suppression.
PMID 15205536·Science·2004
7-preclinical
Eme1 is involved in DNA damage processing and maintenance of genomic stability in mammalian cells.
PMID 14609959·EMBO J·2003
7-preclinical
BARD1 participates with BRCA1 in homology-directed repair of chromosome breaks.
PMID 14560035·Mol Cell Biol·2003
7-preclinical
Preclinical testing for aortic endovascular grafts: results of a Food and Drug Administration workshop.
PMID 12021723·J Vasc Surg·2002
6-review
ATP hydrolysis by mammalian RAD51 has a key role during homology-directed DNA repair.
PMID 11923292·J Biol Chem·2002
7-preclinical
Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.
PMID 11751485·Clin Cancer Res·2001
3-trial
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.
PMID 11352950·J Clin Oncol·2001
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 205 E 64TH ST
NEW YORK, NY 10021 - Phone
- (212) 639-2000
Quick Facts
- NPI
- 1568433522
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile